Table 1.

Summary of pharmacological approaches to acromegaly disease management.

Drug Class	Mechanism of Action	Indications for Use	Citation
Somatostatin Analogs	Directly binds to somatostatin receptors in both the normal pituitary and pituitary adenoma cells to suppress GH secretion.	First-line pharmacotherapy for acromegaly. Suppresses GH secretion in both normal pituitary and adenoma. Also suppresses IGF-1 secretion in the liver.	[4]
Dopamine Receptor Agonists	Directly binds to the pituitary D2R receptors to suppress GH secretion.	Serves as an adjunctive therapy, less effective than somatostatin analogs at GH and IGF-1 management.	[4]
GH- Receptor Agonists	Lowers IGF-1 levels via competitive inhibition of endogenous GH binding to GH receptors. No increased adverse events were associated with long-term therapy.	Adjunctive therapy, unable to suppress GH secretion but lowers IGF-1 by competitive inhibition of endogenous GH binding to hepatocyte receptors.	[4]